Company
Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. We are developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide.
Mission
We develop revolutionary remedies for a healthy, happy world.
Vision
We strive to enable access to treatment options for patients for whom no effective standard of care exists. We aim to be one of the first Asian biologics companies to advance a novel biologic product from pre-clinical studies to BLA submission and commercial launch, and we are developing a portfolio of novel solutions to treat serious diseases for patients worldwide.
Values
Revolutionary
Exploring new frontiers of innovation and treatments
Brave
Striving to improve and drive bold initiatives to deliver best outcomes for patients
Collaborative
Working together to address needs of patients, physicians and customers
Passionate
Improving the standard of care for patients through our pursuit of innovative biological therapies
Trustworthy
Building trust with employees and partners through transparency, consistency, and reliability
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of global Phase III clinical trials and the receipt of orphan drug designation. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment
- 7 July 2020
Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia
- 6 January 2020
Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease
- 22 October 2019
Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies
- 9 September 2019
Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies
- 19 November 2018
Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”
- 19 November 2018
